Search Result

Results for "

Pim-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Pim (22) Apoptosis (6) Autophagy (1) DAPK (1) FLT3 (1) PKD (2) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (21) Cardiovascular Disease (1) Inflammation/Immunology (1)

Inhibitors & Agonists

Recombinant Proteins

Antibodies

Targets Recommended: Pim

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16576A

SMI-4a TCS-Pim-1-4a	Pim	Cancer
SMI-4a (TCS-PIM-1-4a) is a poten, selective, cell-permeable and ATP-competitive *Pim-1* inhibitor with an IC₅₀ of 24 μM and a K_i of 0.6 μM. SMI-4a also inhibits *Pim-2* (IC₅₀ of 100 μM), and does not significantly inhibit the other serine/threonine- or tyrosine-kinases. SMI-4a has anticancer activity .

HY-RS10550

PIM2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PIM2 Human Pre-designed siRNA Set A contains three designed siRNAs for PIM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PIM2 Human Pre-designed siRNA Set A PIM2 Human Pre-designed siRNA Set A

HY-RS10551

Pim2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pim2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pim2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pim2 Mouse Pre-designed siRNA Set A Pim2 Mouse Pre-designed siRNA Set A

HY-RS10552

Pim2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Pim2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pim2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pim2 Rat Pre-designed siRNA Set A Pim2 Rat Pre-designed siRNA Set A

HY-157404

Pim-1/2 kinase inhibitor 2	Pim	Cancer
Pim-1/2 kinase inhibitor 2 (compound 5b) is a competitive *PIM-1* and PIM-2 kinase inhibitor with IC₅₀s of 1.31 μM and 0.67 μM, respectively. Pim-1/2 kinase inhibitor 2 shows in-vitro low cytotoxicity against normal human lung fibroblast Wi-38 cell line and potent in-vitro anticancer activity against myeloid leukaemia (NFS-60), liver (HepG-2), prostate (PC-3), and colon (Caco-2) cancer cell lines .

HY-13287A

SGI-1776	Pim Apoptosis Autophagy	Inflammation/Immunology
SGI-1776 is an inhibitor of Pim kinases, with IC₅₀s of 7 nM, 363 nM, and 69 nM for Pim-1, Pim-2 and Pim-3, respectively ^[2] .

HY-18095

CX-6258

Pim Cancer

CX-6258 is a potent and kinase selective pan-Pim kinases inhibitor, with IC₅₀s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .

CX-6258	Pim	Cancer
CX-6258 is a potent and kinase selective *pan-Pim* kinases inhibitor, with IC₅₀*s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2* and Pim-3, respectively .

HY-18095A

CX-6258 hydrochloride hydrate	Pim	Cancer
CX-6258 hydrochloride hydrate is a potent and kinase selective *pan-Pim* kinases inhibitor, with IC₅₀*s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2* and Pim-3, respectively .

HY-18095B

CX-6258 hydrochloride	Pim	Cancer
CX-6258 hydrochloride is a potent and kinase selective *pan-Pim* kinases inhibitor, with IC₅₀*s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2* and Pim-3, respectively .

HY-160006

PIM-IN-2	Pim	Cancer
PIM-IN-2 (Pim-2) is a *Pim* kinases inhibitor (IC₅₀ = 25 nM). PIM-IN-2 promotes cell survival, is antiapoptotic, and has exhibited an elevated level of expression in a variety of human tumors .

HY-18086

*TCS PIM-1 1* 3 Publications Verification SC 204330	Pim	Cancer
TCS PIM-1 1 (SC 204330) is a potent, selective and ATP-competitive *Pim-1* kianse inhibitor with an IC₅₀ of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2 (IC₅₀s >20000 nM) .

HY-101947

SMI-16a 3 Publications Verification Pim1/2 Kinase Inhibitor VI	Pim	Cancer
SMI-16a is a selective *Pim* kinase inhibitor with IC₅₀ values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.

HY-101783

GNE-955

Pim Cancer

GNE-955 is a potent and orally active pan Pim kinase inhibitor with K_is of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.

GNE-955	Pim	Cancer
GNE-955 is a potent and orally active pan Pim kinase inhibitor with K_is of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.

HY-129163

HJ-PI01 10-Acetylphenoxazine	Pim	Cancer
HJ-PI01 (10-Acetylphenoxazine) is an orally active *Pim-2* inhibitor. HJ-PI01 induces apoptosis and autophagic cell death of cancer cells. HJ-PI01 inhibits tumor growth in MDA-MB-231 xenograft mice. HJ-PI01 can be used for cancer research .

HY-120758

SEL24-B489	Pim FLT3 Apoptosis	Cancer
SEL24-B489 is a potent, type I, orally active, dual *PIM* and FLT3-ITD inhibitor, with K_d values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively .

HY-12830

M-110	Pim	Cancer
M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for *PIM-3* (IC₅₀=47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC₅₀s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC₅₀s of 0.6 to 0.9 μM .

HY-123983

HS56	Pim DAPK	Cardiovascular Disease
HS56 is an ATP-competitive dual *Pim/DAPK3* inhibitor with K_i values of 0.26, 0.208, 2.94, and ＞100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively. HS56 inhibits LC20 phosphorylation and smooth muscle contraction. HS56 decreases blood pressure in spontaneously hypertensive mice. HS56 can be used in research of hypertension .

HY-16976

GDC-0339 2 Publications Verification	Pim	Cancer
GDC-0339 is a potent, orally bioavailable and well tolerated *pan-Pim* kinase inhibitor, with K_i*s of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2* and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma ^[2].

HY-15698A

CRT0066101 dihydrochloride 2 Publications Verification	PKD Pim Apoptosis	Cancer
CRT0066101 dihydrochloride is a potent and orally active PKD inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for PKD1, *PKD2, and PKD3, respectively . CRT0066101 dihydrochloride is also a potent PIM2* inhibitor with an IC₅₀ of ~135.7 nM. CRT0066101 dihydrochloride has anticancer effects ^[2].

HY-15698

CRT0066101	PKD Pim Apoptosis	Cancer
CRT0066101 is a potent and orally active PKD inhibitor with IC₅₀ values of 1 nM, 2.5 nM and 2 nM for PKD1, *PKD2, and PKD3, respectively . CRT0066101 is also a potent PIM2* inhibitor with an IC₅₀ of ~135.7 nM. CRT0066101 has anticancer effects ^[2].

HY-19322B

PIM-447 dihydrochloride 3 Publications Verification LGH447 dihydrochloride	Pim Apoptosis	Cancer
PIM447 dihydrochloride (LGH447 dihydrochloride) is a potent, orally available, and selective pan-PIM kinase inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 dihydrochloride displays dual antimyeloma and bone-protective effects. PIM447 dihydrochloride induces apoptosis ^[2].

HY-19322

PIM447 3 Publications Verification LGH447
PIM447 (LGH447) is a potent, orally available, and selective pan-PIM kinase inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 displays dual antimyeloma and bone-protective effects. PIM447 induces apoptosis ^[2].

HY-101870B

Uzansertib phosphate INCB053914 phosphate	Pim	Cancer
Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC₅₀s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines .

HY-101870

Uzansertib INCB053914	Pim	Cancer
Uzansertib (INCB053914) is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC₅₀s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib has broad anti-proliferative activity against a variety of hematologic tumor cell lines .

HY-19322C

*(1S,3R,5R)-PIM447 dihydrochloride* (1S,3R,5R)-LGH447 dihydrochloride	Pim	Cancer
(1S,3R,5R)-PIM447 (dihydrochloride) an *PIM* inhibitor extracted from patent US 20100056576 A1, compound example 72, has IC₅₀ values of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3.

HY-111552

PIM1-IN-1	Pim	Cancer
PIM1-IN-1 is a potent and highly selective *PIM1/3* inhibitor, with IC₅₀s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC₅₀ of 262 nM. PIM1-IN-1 shows no obvious effect on FLT3 or hERG binding. Antiproliferative and anti-cancer activity .

HY-126379

CDDO-2P-Im	Apoptosis	Cancer
CDDO-2P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-2P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

	PIM2 Protein, Human Pim2; Serine/threonine-protein kinase Pim-2; Pim-2h	Human	E. coli
	The PIM2 protein is a proto-oncogene with serine/threonine kinase activity that critically promotes cell survival and proliferation through multiple mechanisms. It enhances MYC stability and transcriptional activity, explaining the synergistic effect in tumorigenesis. PIM2 Protein, Human is the recombinant human-derived PIM2 protein, expressed by E. coli , with tag free. The total length of PIM2 Protein, Human is 311 a.a., .

	PIM2 Protein, Human (His) Pim2; Serine/threonine-protein kinase Pim-2; Pim-2h	Human	E. coli
	The PIM2 protein is a proto-oncogene with serine/threonine kinase activity that critically promotes cell survival and proliferation through multiple mechanisms. It enhances MYC stability and transcriptional activity, explaining the synergistic effect in tumorigenesis. PIM2 Protein, Human (His) is the recombinant human-derived PIM2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of PIM2 Protein, Human (His) is 311 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.